AstraZeneca's Blockbuster Lung Cancer Drug Has a Huge Sales Boost Ahead

Oncologists' ability to treat a certain subset of early-stage lung cancer patients after they've had tumors removed is about to get a big improvement. On Friday, AstraZeneca (NYSE: AZN) released clinical trial results that show treatment with Tagrisso tablets reduced the risk of disease recurrence or death by 83% in the adjuvant setting.